Anzeige
Mehr »
Login
Samstag, 27.07.2024 Börsentäglich über 12.000 News von 684 internationalen Medien
BRANDNEUE Gold-Entdeckung: OMEGA stößt auf HOCHGRAD-Gold! 18,98 m @ 6,22 g/t Gold! TA-Preis "STARKER-KAUF"
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EW0P | ISIN: US00808Y4061 | Ticker-Symbol: EJU0
Tradegate
24.07.24
17:17 Uhr
0,354 Euro
+0,018
+5,36 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
AETHLON MEDICAL INC Chart 1 Jahr
5-Tage-Chart
AETHLON MEDICAL INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,3360,35226.07.
0,3280,34426.07.

Aktuelle News zur AETHLON MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
28.06.Aethlon Medical, Inc. (NASDAQ:AEMD) Q4 2024 Earnings Call Transcript8
28.06.Earnings call: Aethlon Medical reports FY 2024 financial results6
27.06.Aethlon Medical Inc reports results for the quarter ended in March - Earnings Summary4
27.06.AETHLON MEDICAL INC - 10-K, Annual Report2
27.06.AETHLON MEDICAL INC - 8-K, Current Report2
27.06.Aethlon Medical, Inc.: Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update174Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 27, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to...
► Artikel lesen
26.06.Aethlon Medical FY 2024 Earnings Preview4
18.06.Aethlon Charges Ahead on Approval of Cancer Drug4
17.06.(AEMD) - Analyzing Aethlon Medical's Short Interest1
06.06.Why Is Aethlon Medical (AEMD) Stock Up 82% Today?22
03.06.Aethlon Flat as Clinical Trial Results Released18
03.06.Aethlon Medical, Inc.: Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies156Phase 1 Clinical Trials of the Hemopurifier® Designed to Include Patients With Solid Tumors Who Have Stable or Progressive Disease During Anti-PD-1 Monotherapy Treatment, Such as Keytruda® of Opdivo®...
► Artikel lesen
17.05.AETHLON MEDICAL INC - 8-K, Current Report7
15.05.Aethlon Medical announces pricing of $4.7 million public offering14
13.05.AETHLON MEDICAL INC - S-1/A, General form for registration of securities4
10.05.What's Going On With Medical Therapeutic Firm Aethlon Medical On Friday?4
10.05.Aethlon jumps on positive results from in vitro binding study of Hemopurifier device6
10.05.Aethlon Medical Stock Surges In Pre-market On Positive Hemopurifier Trial Results-
10.05.AETHLON MEDICAL INC - 8-K, Current Report5
10.05.Aethlon Medical, Inc.: Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier in Removing Extracellular Vesicles From Cancer Patient Plasma110Translational Study Provides Pre-Clinical Evidence to Support The Design of a Phase 1 Study of the Hemopurifier In Cancer Patients With Solid Tumors Treated With Anti-PD-1 Antibodies Aethlon Medical...
► Artikel lesen
Seite:  Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1